Article Details

Atypical Hemolytic Uremic Syndrome Market Expected Rise, 2034 | - openPR.com

Retrieved on: 2025-04-27 20:43:43

Tags for this article:

Click the tags to see associated articles and topics

Atypical Hemolytic Uremic Syndrome Market Expected Rise, 2034 | - openPR.com. View article details on hiswai:

Summary

The article discusses the epidemiology and market dynamics of atypical hemolytic uremic syndrome (aHUS), a rare blood disorder. It highlights increasing prevalence, significant pharmaceutical investments, and emerging therapies, including monoclonal antibodies like eculizumab and crovalimab. Key players include Alexion Pharmaceuticals, with a focus on the U.S. market.

Article found on: www.openpr.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo